Stamos Capital Partners, L.P. Vertex Pharmaceuticals Inc Transaction History

Stamos Capital Partners, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $43,209 - $53,408	-110 Reduced 9.09%	1,100 $515,000
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $12,230 - $13,382	-30 Reduced 2.42%	1,210 $505,000
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $559,090 - $669,408	-1,630 Reduced 56.79%	1,240 $504,000
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $970,576 - $1.04 Million	2,870 New	2,870 $998,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Stamos Capital Partners, L.P., based on Form 13F filings with the SEC.

Stay updated on Stamos Capital Partners, L.P. with notifications on news.